Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00384566
Registration number
NCT00384566
Ethics application status
Date submitted
5/10/2006
Date registered
6/10/2006
Date last updated
24/06/2015
Titles & IDs
Public title
A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure
Query!
Scientific title
The CAMERA Study: CArvedilol MEtoprolol Respiratory Assessment Investigator Trial
Query!
Secondary ID [1]
0
0
CP-03/04
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Heart Failure
0
0
Query!
Chronic Obstructive Airway Disease
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Carvedilol
Treatment: Drugs - Metoprolol
Experimental: 1 -
Active Comparator: 2 -
Treatment: Drugs: Carvedilol
anit hypertensive medication
Treatment: Drugs: Metoprolol
Anti hypertensive medication
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Respiratory function
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Each study visit
Query!
Primary outcome [2]
0
0
NYHA class with the use of the 7 point scale (Packer).
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline, cross over, end of study
Query!
Primary outcome [3]
0
0
Minnesota "living with Heart Failure" questionnaire.
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline, cross over, end of study
Query!
Primary outcome [4]
0
0
U+E
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Screening, cross over, end of study
Query!
Primary outcome [5]
0
0
BP and HR
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
every visit
Query!
Primary outcome [6]
0
0
plasma N-terminal pro-BNP
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Screening, cross over, end of study
Query!
Eligibility
Key inclusion criteria
- males and females over 18 years of age
- Documented CHF (NYHA class II-IV symptoms)
- Airflow obstruction defined as patients with symptomatic obstructive respiratory
disease as manifest by any of the following Symptoms of wheeze, primarily attributed
to airflow obstruction Requirement for intermittent or regular bronchodilator therapy
FEV1 less than 70% predicted pre-salbutamol
- Confirmed written informed consent.
- Clinically indicated to receive ß-blockade.
- No evidence of heart block on ECG.
- Patients will be in one of the following categories:
Currently on carvedilol Currently on Toprol-XL or Metoprolol tartrate Currently on
bisoprolol Clinically indicated to receive ß adrenoceptor blockade but not currently
prescribed a ß-blocker.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Women lactating, pregnant or of childbearing potential not using a reliable
contraceptive method.
- Patients who had received an investigational new drug within the last 4 weeks.
- Patients with a history of a psychological illness or condition such as to interfere
with the patient's ability to understand the requirements of the study.
- Laboratory parameters:
Creatinine >0.30 mmol/l Liver function tests 3x ULN
- Recent (<12 months) myocarditis
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
1/06/2005
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
0
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
The Alfred
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Roche Pharma AG
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study looks at the effect of two drugs (carvedilol and metoprolol) which are used for
patients with CHF (chronic heart failure).
These agents are beta-blockers and, although effective in heart failure, may cause increases
in airways tone and thus limit air getting into the lower parts of the lungs. Carvedilol is
more active at blocking the receptor that opens up the airways and therefore theoretically
may be more likely to reduce airways tone than metoprolol, although this has never been
studied in patients with heart failure, and that is the purpose of the present study.
We are looking to enrol 45 patients with heart failure and mild obstruction to the flow of
air in their lungs. Patients will be randomised to either carvedilol or metoprolol (standard
doses). Following a minimum of 2 weeks of therapy of study medication the patient will
undergo a study day involving an assessment of their lung function, an assessment of their
heart failure, a "living with heart failure" questionnaire, blood tests and blood pressure
and heart rate readings.
Patients will then be crossed over to the alternate medication. Following 2 weeks on the
target dose the patient will undergo their second study day which will be the same as the
first.
The results obtained from each study day will be compared.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00384566
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Henry Krum, Professor
Query!
Address
0
0
Monash University / Alfred Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00384566
Download to PDF